Autologous Stem Cell Transplant, Multiple Myeloma
Conditions
Keywords
Drug therapy, Ixazomib citrate
Brief summary
The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to induction therapy followed by high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
Detailed description
The investigational drug being tested in this study is called ixazomib citrate. Ixazomib citrate is being tested to slow disease progression and improve overall survival in people who have NDMM and who have had any type of positive response to induction therapy followed by HDT and ASCT. This study will look at the effect ixazomib citrate has on the length of time that participants are free of progressive disease (PD) and their overall survival (OS). The study enrolled 656 participants. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need, or if the disease has progressed and the information is required for planning the next treatment): * Ixazomib citrate 3 mg for the first 4 cycles, then 4 mg for the remaining 22 cycles * Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient. All participants will be asked to take one capsule on Days 1, 8 and 15 of each 28-day cycle, for up to 26 cycles (approximately 24 months). This multi-center trial will be conducted globally. The overall time to participate in this study is up to 107 months. Participants will make 28 visits to the clinic during the treatment period and will continue to make visits after treatment has ended. During this initial follow up period, participants will be assessed for disease status with follow up every 12 weeks. After the next line of therapy begins, follow-up will occur every 12 weeks until death or termination of the study.
Interventions
DRUGIxazomib Citrate
Ixazomib citrate capsules
DRUGPlacebo
Ixazomib citrate placebo-matching capsules
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult male or female participants 18 years or older with a confirmed diagnosis of symptomatic multiple myeloma according to standard criteria. 2. Documented results of cytogenetics/ fluorescence in situ hybridization (FISH) obtained at any time before transplant, and International Staging System (ISS) staging at the time of diagnosis available. 3. Underwent standard of care (SOC) induction therapy (induction therapy must include proteasome inhibitor (PI) and/or immunomodulating drugs (IMiD)-based regimens as primary therapy for multiple myeloma), followed by a single autologous stem cell transplant (ASCT) with a high-dose melphalan (200 mg/m\^2) conditioning regimen, within 12 months of diagnosis. Vincristine, Adriamycin \[doxorubicin\], and dexamethasone (VAD) is not an acceptable induction therapy for this trial. 4. Started screening no earlier than 75 days after transplant, completed screening within 15 days, and randomized no later than 115 days after transplant. 5. Must have not received post-ASCT consolidation therapy. 6. Documented response to ASCT (PR, VGPR, CR/stringent complete response \[sCR\]) according to IMWG criteria. 7. ECOG performance status of 0 to 2. 8. Female participants who: * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, AND * Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, postovulation methods for the female partner\] and withdrawal are not acceptable methods of contraception.) Male participants, even if surgically sterilized (ie, status postvasectomy), who: * Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, AND * Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, postovulation methods for the female partner\] and withdrawal are not acceptable methods of contraception.) 9. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care. 10. Suitable venous access for the study-required blood sampling. 11. Is willing and able to adhere to the study visit schedule and other protocol requirements. 12. Must meet the following clinical laboratory criteria at study entry: * Absolute neutrophil count (ANC) ≥ 1,000 per cubic milliliter (/mm\^3) and platelet count ≥ 75,000/mm\^3. Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before randomization. * Total bilirubin ≤ 1.5 \* the upper limit of the normal range (ULN). * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 \* ULN. * Calculated creatinine clearance ≥ 30 milliliter per minute (mL/min).
Exclusion criteria
1. Multiple myeloma that has relapsed following primary therapy or is not responsive to primary therapy. For this study, stable disease following ASCT will be considered nonresponsive to primary therapy. 2. Double (tandem) ASCT. 3. Radiotherapy within 14 days before the first dose of study drug. 4. Diagnosed or treated for another malignancy within 5 years before randomization or previously diagnosed with another malignancy with evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection. 5. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period. 6. Major surgery within 14 days before randomization. 7. Central nervous system involvement. 8. Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before randomization. 9. Diagnosis of Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome. 10. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months. 11. Systemic treatment with strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before randomization in the study. 12. Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive. 13. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens (eg, peripheral neuropathy that is Grade 1 with pain or Grade 2 or higher of any cause). 14. Psychiatric illness/social situation that would limit compliance with study requirements. 15. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent. 16. Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment. 17. Treatment with any investigational products within 60 days before the first dose of the study drug regimen.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months) | PFS was defined as the time from the date of randomization to the date of first documentation of PD, as evaluated by an independent review committee (IRC) according to International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurred first. PD was defined as ≥25% increase from lowest value in: serum/urine M component; participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved free light chain (FLC) levels must be \>10 milligrams per deciliter (mg/dL); participants without measurable serum, urine M-protein levels and FLC levels, bone marrow plasma cell percent must have been ≥10%; new bone lesions/soft tissue plasmacytomas development/existing bone lesions/soft tissue plasmacytomas size increase; hypercalcemia development. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Any Best Response Category Before PD or Subsequent Therapy | Randomization up to EOT (up to 24 months) and thereafter every 4 weeks until initiation of the next line of therapy (up to 107 months) | Response was assessed according to IMWG criteria. Best response includes partial response (PR), very good partial response (VGPR) and complete response (CR). PR as per IMWG criteria is 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to less than (\<)200 milligrams (mg) per 24 hours. VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours. CR is negative immunofixation of serum and urine and disappearance of soft tissue plasmacytomas and \<5% plasma cells in bone marrow. Stringent CR (sCR) is CR and normal FLC ratio and absence of clonal plasma cells (PCs) by immunohistochemistry or 2- to 4-color flow cytometry. The decimal values of percentages were subjected to rounding off. |
| Time to Progression (TTP) | Randomization up to PD (up to 107 months) | TTP is defined as the time from the date of randomization to the date of first documentation of PD, using IMWG criteria. PD is defined as ≥25% increase from lowest value in: serum/urine M-component; participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels must be \>10mg/dL; participants without measurable serum, urine M-protein levels and FLC levels, bone marrow plasma cell percent must be ≥10%;new bone lesions/soft tissue plasmacytomas development/existing bone lesions/soft tissue plasmacytomas size rise; hypercalcaemia development. Participants without documentation of PD at the time of analysis were censored at the date of last response assessment that is stable disease or better. |
| Second Progression Free Survival (PFS2) | Randomization up to EOT (24 months); thereafter followed up every 4 weeks until initiation of next-line therapy and then every 12 weeks until second progressive disease (PD2) or death (up to 107 months) | PFS2 is defined as the time from the date of randomization to the date of objective disease progression on next line treatment or death from any cause (whichever occurs first). PD is defined as ≥25% increase from lowest value in: serum/urine M-component; participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels must be \>10 mg/dL; participants without measurable serum, urine M-protein levels and FLC levels, bone marrow plasma cell percent must be ≥10%; new bone lesions/soft tissue plasmacytomas development/existing bone lesions/soft tissue plasmacytomas size rise; hypercalcaemia development. |
| Time to Start of the Next Line of Therapy | Randomization up to 107 months | Time to start of the next line of therapy was defined as the time from the date of randomization to the date of initiation dose of the next line of antineoplastic therapy following study treatment or death due to any cause, whichever occurred first. Participants who never took antineoplastic therapy were censored at the date of last contact or death. |
| Time to End of the Next Line of Therapy | Randomization up to 107 months | Time to end of the next line of therapy was defined as the time from the date of randomization to the date of last dose of the next line of antineoplastic therapy following study treatment or death due to any cause, whichever occurred first or date of last contact for participants who never took antineoplastic therapy. |
| Duration of the Next Line of Therapy | Up to 107 months | Duration of the next line of therapy was defined as the time from the date of the first dose of the next line of therapy to the date of the last dose of the next antineoplastic therapy following study treatment or death due to any cause, whichever occurred first. Duration of the next line of therapy was analyzed on those participants who received the next line of therapy following the study treatment and duration was summarized using Kaplan-Meier method. |
| Percentage of Participants Who Develop a New Primary Malignancy | Up to 107 months | The decimal values of percentages were subjected to rounding off. |
| Number of Participants With Conversion to Minimal Residual Disease (MRD) Negative | Baseline up to EOT (up to 24 months) | MRD negativity (MRD-) is defined as absence of MRD and MRD positivity (MRD+) is defined as presence of MRD. The conversion rate from MRD positive to MRD negative was assessed and reported. Bone marrow aspirates and blood samples were sent to a central laboratory and were assessed for MRD using flow cytometry and a sequencing methodology. |
| Number of Participants With Maintenance of MRD Negativity | Up to EOT (up to 24 months) | MRD negativity is defined as absence of MRD and MRD positivity is defined as presence of MRD. The maintenance of MRD negativity up to the end of treatment was assessed and reported in participants converting from MRD+ at Baseline to MRD negative. Bone marrow aspirates and blood samples were sent to a central laboratory and were assessed for MRD using flow cytometry and a sequencing methodology. |
| Correlation Between MRD Status and Progression Free Survival (PFS) | From randomization up to 107 months | PFS is defined as the time from the date of randomization to the date of first documentation of PD as evaluated by an IRC according to IMWG criteria, or death due to any cause, whichever occurred first, assessed for up to 107 months in this outcome measure. |
| Overall Survival (OS) | Randomization up to end of follow up period (up to 107 months) | OS was measured as the time from the date of randomization to the date of death. |
| OS Benefits in a High-Risk Population | Randomization up to 107 months | High-risk population included but was not limited to participants carrying deletion (del)17, t(4:14), t(14:16), amplification (ampl) 1q, del13, or del1p. OS was measured as the time from the date of randomization to the date of death. |
| PFS Benefits in a High-Risk Population | Randomization up to 107 months | High-risk population included but not be limited to participants carrying deletion (del)17, t(4:14), t(14:16), amplification (ampl) 1q, del13, or del1p. PFS was defined as the time from the date of randomization to the date of first documentation of PD, as evaluated by an independent review committee according to IMWG criteria, or death due to any cause (whichever occurs first). PD is defined as ≥25% increase from lowest value in: serum/urine M-component; participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels must be \>10mg/dL; participants without measurable serum, urine M-protein levels and FLC levels, bone marrow plasma cell percent must be ≥10%;new bone lesions/soft tissue plasmacytomas development/existing bone lesions/soft tissue plasmacytomas size rise; hypercalcaemia development. |
| Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score | Baseline up to EOT (up to Month 24) | ECOG performance status assesses a participant's performance status on a 6-point scale ranging from 0=fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self-care, confined to bed/chair \>50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5=dead. Lower scores indicate improvement. |
| Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) or Serious Adverse Events (SAEs) | Up to 107 months | An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation subject administered a drug. An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug. An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital abnormality or birth defect, an important medical event. |
| Number of Participants With Markedly Abnormal Clinical Laboratory Values Reported as TEAEs | Up to 107 months | Laboratory tests included chemistry, hematology and urinalysis. Abnormal laboratory value was assessed as an AE if the value led to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from baseline. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug. |
| Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Domain Score | Baseline up to EOT (up to Month 24) | The EORTC QLQ-C30 is a 30-item questionnaire used to assess the health-related quality of life of cancer patients. GHS/QoL domain is based on questions 29 (How would you rate your overall health during the past week?) and 30 (How would you rate your overall quality of life during the past week?) of the EORTC QLQ-C30 where the study participants' self-reported responses to the questions on a 7-point scale (1=very poor to 7=excellent). The raw GHS/QoL domain scores were linearly transformed to a scale ranging 0 (worse outcome) to 100 (best outcome), with higher scores indicating better quality of life. The change from baseline in EORTC QLQ-C30 GHS/QoL domain was evaluated by treatment group. |
| Plasma Concentration of Ixazomib | Day 1 of Cycle 1: 1 hour and 4 hours post-dose; Predose on Days 8 and 15 of Cycle 1, Days 1 and 8 of Cycle 2, Day 1 of Cycles 3 through 10 (each cycle length= 28 days) | Plasma concentrations of the complete hydrolysis product of ixazomib citrate (ixazomib) were measured using a validated Liquid Chromatography-tandem Mass Spectrometry (LC/MS/MS) assay. |
| Time to Resolution of Peripheral Neuropathy (PN) Events | Up to 107 months | Peripheral neuropathy is defined as the TEAE in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to Medical Dictionary for Regulatory Activities (MedDRA). A PN event is considered as improved if the event improves from the maximum grade. That is, all the grades recorded after the maximum grade is less than the maximum grade. Time to improvement is defined as the time from the initial onset date (inclusive) of the maximum grade to the first onset date that the toxicity grade is below the maximum grade with no higher grade thereafter, or the resolution date, whichever occurs first. |
| Time to Improvement of PN Events | Up to 107 months | PN is defined as the treatment-emergent adverse event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the Medical Dictionary for Regulatory Activities (MedDRA). A PN event is considered as resolved if its final outcome is resolved with no subsequent PN event of the same preferred term occurring on the resolution date or the day before and after. A PN event is considered as improved if the event improves from the maximum grade. That is, all the grades recorded after the maximum grade is less than the maximum grade. Time to improvement is defined as the time from the initial onset date (inclusive) of the maximum grade to the first onset date that the toxicity grade is below the maximum grade with no higher grade thereafter, or the resolution date, whichever occurs first. |
| Correlation Between MRD Status and Overall Survival (OS) | From randomization up to 107 months | OS was measured as the time from the date of randomization to the date of death, assessed for up to 107 months in this outcome measure. |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Portugal, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States
Participant flow
Recruitment details
Participants enrolled at 167 sites globally to take part in this study from 16 July 2014 to 8 September 2023.
Pre-assignment details
Participants with newly diagnosed multiple myeloma (NDMM) who underwent induction therapy according to regional standard of care (SoC), followed by high-dose melphalan (200 milligrams per meter square \[mg/m\^2\]) and Autologous Stem Cell Transplant (ASCT) were enrolled in a 3:2 ratio to receive ixazomib citrate or placebo.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons. | 261 |
| Ixazomib Citrate Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons. Participants who had any dose reductions due to AEs were not dose escalated. | 395 |
| Total | 656 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 8 | 7 |
| Overall Study | Reason Not Specified | 2 | 5 |
| Overall Study | Withdrawal by Subject | 45 | 61 |
Baseline characteristics
| Characteristic | Placebo | Ixazomib Citrate | Total |
|---|---|---|---|
| Age, Continuous | 58.2 years STANDARD_DEVIATION 7.92 | 56.8 years STANDARD_DEVIATION 8.17 | 57.4 years STANDARD_DEVIATION 8.1 |
| Age, Customized ≥60 and <75 years | 134 Participants | 166 Participants | 300 Participants |
| Age, Customized <60 years | 127 Participants | 229 Participants | 356 Participants |
| Body Surface Area (BSA) | 1.87 m^2 STANDARD_DEVIATION 0.221 | 1.88 m^2 STANDARD_DEVIATION 0.235 | 1.88 m^2 STANDARD_DEVIATION 0.229 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 11 Participants | 14 Participants | 25 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 240 Participants | 362 Participants | 602 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 10 Participants | 19 Participants | 29 Participants |
| Height | 168.73 cm STANDARD_DEVIATION 10.347 | 169.71 cm STANDARD_DEVIATION 10.004 | 169.32 cm STANDARD_DEVIATION 10.145 |
| Race/Ethnicity, Customized Asian | 36 Participants | 59 Participants | 95 Participants |
| Race/Ethnicity, Customized Black or African American | 3 Participants | 7 Participants | 10 Participants |
| Race/Ethnicity, Customized Not Reported | 8 Participants | 12 Participants | 20 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 2 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 213 Participants | 315 Participants | 528 Participants |
| Region of Enrollment Argentina | 0 Participants | 3 Participants | 3 Participants |
| Region of Enrollment Australia | 11 Participants | 17 Participants | 28 Participants |
| Region of Enrollment Austria | 2 Participants | 2 Participants | 4 Participants |
| Region of Enrollment Belgium | 5 Participants | 5 Participants | 10 Participants |
| Region of Enrollment Brazil | 3 Participants | 5 Participants | 8 Participants |
| Region of Enrollment Czech Republic | 12 Participants | 30 Participants | 42 Participants |
| Region of Enrollment Denmark | 11 Participants | 20 Participants | 31 Participants |
| Region of Enrollment France | 7 Participants | 11 Participants | 18 Participants |
| Region of Enrollment Germany | 26 Participants | 50 Participants | 76 Participants |
| Region of Enrollment Greece | 22 Participants | 38 Participants | 60 Participants |
| Region of Enrollment Hungary | 9 Participants | 16 Participants | 25 Participants |
| Region of Enrollment Israel | 12 Participants | 10 Participants | 22 Participants |
| Region of Enrollment Italy | 26 Participants | 24 Participants | 50 Participants |
| Region of Enrollment Japan | 9 Participants | 13 Participants | 22 Participants |
| Region of Enrollment Korea, Republic Of | 17 Participants | 23 Participants | 40 Participants |
| Region of Enrollment Netherlands | 11 Participants | 8 Participants | 19 Participants |
| Region of Enrollment Norway | 6 Participants | 13 Participants | 19 Participants |
| Region of Enrollment Poland | 5 Participants | 10 Participants | 15 Participants |
| Region of Enrollment Portugal | 2 Participants | 8 Participants | 10 Participants |
| Region of Enrollment Singapore | 4 Participants | 8 Participants | 12 Participants |
| Region of Enrollment South Africa | 4 Participants | 3 Participants | 7 Participants |
| Region of Enrollment Spain | 19 Participants | 19 Participants | 38 Participants |
| Region of Enrollment Sweden | 4 Participants | 7 Participants | 11 Participants |
| Region of Enrollment Switzerland | 3 Participants | 0 Participants | 3 Participants |
| Region of Enrollment Taiwan, Province Of China | 3 Participants | 10 Participants | 13 Participants |
| Region of Enrollment Thailand | 1 Participants | 5 Participants | 6 Participants |
| Region of Enrollment Turkey | 10 Participants | 10 Participants | 20 Participants |
| Region of Enrollment Ukraine | 2 Participants | 1 Participants | 3 Participants |
| Region of Enrollment United Kingdom | 14 Participants | 21 Participants | 35 Participants |
| Region of Enrollment United States | 1 Participants | 5 Participants | 6 Participants |
| Sex: Female, Male Female | 99 Participants | 143 Participants | 242 Participants |
| Sex: Female, Male Male | 162 Participants | 252 Participants | 414 Participants |
| Weight | 75.18 kg STANDARD_DEVIATION 14.648 | 75.93 kg STANDARD_DEVIATION 15.989 | 75.63 kg STANDARD_DEVIATION 15.463 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 93 / 261 | 144 / 395 |
| other Total, other adverse events | 229 / 259 | 371 / 394 |
| serious Total, serious adverse events | 51 / 259 | 108 / 394 |
Outcome results
Primary
Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of first documentation of PD, as evaluated by an independent review committee (IRC) according to International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurred first. PD was defined as ≥25% increase from lowest value in: serum/urine M component; participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved free light chain (FLC) levels must be \>10 milligrams per deciliter (mg/dL); participants without measurable serum, urine M-protein levels and FLC levels, bone marrow plasma cell percent must have been ≥10%; new bone lesions/soft tissue plasmacytomas development/existing bone lesions/soft tissue plasmacytomas size increase; hypercalcemia development.
Time frame: Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)
Population: Intent-to-Treat (ITT) population was defined as all participants who were randomized and had post randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Progression Free Survival (PFS) | 21.3 months |
| Ixazomib Citrate | Progression Free Survival (PFS) | 26.5 months |
p-value: 0.00295% CI: [0.582, 0.89]Log Rank
Secondary
Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score
ECOG performance status assesses a participant's performance status on a 6-point scale ranging from 0=fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self-care, confined to bed/chair \>50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5=dead. Lower scores indicate improvement.
Time frame: Baseline up to EOT (up to Month 24)
Population: Safety population was defined as participants who received at least 1 dose of ixazomib citrate or placebo. Overall number of participants analyzed indicates the number of participants with data available for analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score | 0.1 score on a scale | Standard Deviation 0.63 |
| Ixazomib Citrate | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score | 0.0 score on a scale | Standard Deviation 0.54 |
Secondary
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Domain Score
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the health-related quality of life of cancer patients. GHS/QoL domain is based on questions 29 (How would you rate your overall health during the past week?) and 30 (How would you rate your overall quality of life during the past week?) of the EORTC QLQ-C30 where the study participants' self-reported responses to the questions on a 7-point scale (1=very poor to 7=excellent). The raw GHS/QoL domain scores were linearly transformed to a scale ranging 0 (worse outcome) to 100 (best outcome), with higher scores indicating better quality of life. The change from baseline in EORTC QLQ-C30 GHS/QoL domain was evaluated by treatment group.
Time frame: Baseline up to EOT (up to Month 24)
Population: ITT Population was defined as all participants who were randomized and had post randomization data. Overall number of participants analyzed indicates the number of participants with data available for analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Domain Score | -1.7 score on a scale | Standard Error 1.57 |
| Ixazomib Citrate | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Domain Score | -4.1 score on a scale | Standard Error 1.43 |
p-value: 0.07495% CI: [-4.9, 0.2]t-test, 2 sided
Secondary
Correlation Between MRD Status and Overall Survival (OS)
OS was measured as the time from the date of randomization to the date of death, assessed for up to 107 months in this outcome measure.
Time frame: From randomization up to 107 months
Population: ITT population was defined as all participants who were randomized and had post randomization data. Overall number analyzed is the number of participants with data available for analyses. Number analyzed indicates the number of participants available for analysis in the specified category.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo | Correlation Between MRD Status and Overall Survival (OS) | MRD- at Study Entry | NA months |
| Placebo | Correlation Between MRD Status and Overall Survival (OS) | MRD+ at Study Entry | NA months |
| Ixazomib Citrate | Correlation Between MRD Status and Overall Survival (OS) | MRD- at Study Entry | NA months |
| Ixazomib Citrate | Correlation Between MRD Status and Overall Survival (OS) | MRD+ at Study Entry | 105.0 months |
Comparison: MRD- at Study Entryp-value: 0.18295% CI: [0.414, 1.184]Log Rank
Comparison: MRD+ at Study Entryp-value: 0.84795% CI: [0.682, 1.368]Log Rank
Secondary
Correlation Between MRD Status and Progression Free Survival (PFS)
PFS is defined as the time from the date of randomization to the date of first documentation of PD as evaluated by an IRC according to IMWG criteria, or death due to any cause, whichever occurred first, assessed for up to 107 months in this outcome measure.
Time frame: From randomization up to 107 months
Population: ITT population was defined as all participants who were randomized and had post randomization data. Overall number analyzed is the number of participants with data available for analyses. Number analyzed indicates the number of participants available for analysis in the specified category.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo | Correlation Between MRD Status and Progression Free Survival (PFS) | MRD+ at Study Entry | 18.5 months |
| Placebo | Correlation Between MRD Status and Progression Free Survival (PFS) | MRD- at Study Entry | 32.5 months |
| Ixazomib Citrate | Correlation Between MRD Status and Progression Free Survival (PFS) | MRD- at Study Entry | 38.6 months |
| Ixazomib Citrate | Correlation Between MRD Status and Progression Free Survival (PFS) | MRD+ at Study Entry | 23.1 months |
Comparison: MRD- at Study Entryp-value: 0.03495% CI: [0.386, 0.969]Log Rank
Comparison: MRD+ at Study Entryp-value: 0.0195% CI: [0.539, 0.92]Log Rank
Secondary
Duration of the Next Line of Therapy
Duration of the next line of therapy was defined as the time from the date of the first dose of the next line of therapy to the date of the last dose of the next antineoplastic therapy following study treatment or death due to any cause, whichever occurred first. Duration of the next line of therapy was analyzed on those participants who received the next line of therapy following the study treatment and duration was summarized using Kaplan-Meier method.
Time frame: Up to 107 months
Population: ITT Population was defined as all participants who were randomized and had post randomization data. Overall number of participants analyzed indicates the number of participants who started next line of therapy.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Duration of the Next Line of Therapy | 12.3 months |
| Ixazomib Citrate | Duration of the Next Line of Therapy | 9.6 months |
95% CI: [0.959, 1.45]
Secondary
Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) or Serious Adverse Events (SAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation subject administered a drug. An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug. An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital abnormality or birth defect, an important medical event.
Time frame: Up to 107 months
Population: Safety Population was defined as participants who received at least 1 dose of ixazomib citrate or placebo.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) or Serious Adverse Events (SAEs) | TEAEs | 241 Participants |
| Placebo | Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) or Serious Adverse Events (SAEs) | SAEs | 51 Participants |
| Ixazomib Citrate | Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) or Serious Adverse Events (SAEs) | TEAEs | 382 Participants |
| Ixazomib Citrate | Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) or Serious Adverse Events (SAEs) | SAEs | 108 Participants |
Secondary
Number of Participants With Conversion to Minimal Residual Disease (MRD) Negative
MRD negativity (MRD-) is defined as absence of MRD and MRD positivity (MRD+) is defined as presence of MRD. The conversion rate from MRD positive to MRD negative was assessed and reported. Bone marrow aspirates and blood samples were sent to a central laboratory and were assessed for MRD using flow cytometry and a sequencing methodology.
Time frame: Baseline up to EOT (up to 24 months)
Population: ITT population was defined as all participants who were randomized and had post randomization data. Overall number of participants analyzed indicates the number of participants with MRD+ at Baseline.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With Conversion to Minimal Residual Disease (MRD) Negative | 27 Participants |
| Ixazomib Citrate | Number of Participants With Conversion to Minimal Residual Disease (MRD) Negative | 39 Participants |
p-value: 0.814Fisher Exact
Secondary
Number of Participants With Maintenance of MRD Negativity
MRD negativity is defined as absence of MRD and MRD positivity is defined as presence of MRD. The maintenance of MRD negativity up to the end of treatment was assessed and reported in participants converting from MRD+ at Baseline to MRD negative. Bone marrow aspirates and blood samples were sent to a central laboratory and were assessed for MRD using flow cytometry and a sequencing methodology.
Time frame: Up to EOT (up to 24 months)
Population: ITT population was defined as all participants who were randomized and had post randomization data. Overall number analyzed is the number of participants who converted from MRD+ at Baseline to MRD negative.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With Maintenance of MRD Negativity | 25 Participants |
| Ixazomib Citrate | Number of Participants With Maintenance of MRD Negativity | 37 Participants |
p-value: 0.805Fisher Exact
Secondary
Number of Participants With Markedly Abnormal Clinical Laboratory Values Reported as TEAEs
Laboratory tests included chemistry, hematology and urinalysis. Abnormal laboratory value was assessed as an AE if the value led to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from baseline. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.
Time frame: Up to 107 months
Population: Safety Population was defined as participants who received at least 1 dose of ixazomib citrate or placebo.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With Markedly Abnormal Clinical Laboratory Values Reported as TEAEs | 36 Participants |
| Ixazomib Citrate | Number of Participants With Markedly Abnormal Clinical Laboratory Values Reported as TEAEs | 81 Participants |
Secondary
OS Benefits in a High-Risk Population
High-risk population included but was not limited to participants carrying deletion (del)17, t(4:14), t(14:16), amplification (ampl) 1q, del13, or del1p. OS was measured as the time from the date of randomization to the date of death.
Time frame: Randomization up to 107 months
Population: ITT population was defined as all participants who were randomized and had post randomization data. Overall number analyzed is the number of participants present in the high-risk group.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | OS Benefits in a High-Risk Population | 69.0 months |
| Ixazomib Citrate | OS Benefits in a High-Risk Population | 64.2 months |
p-value: 0.90595% CI: [0.583, 1.613]Log Rank
Secondary
Overall Survival (OS)
OS was measured as the time from the date of randomization to the date of death.
Time frame: Randomization up to end of follow up period (up to 107 months)
Population: ITT population was defined as all participants who were randomized and had post randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Overall Survival (OS) | NA months |
| Ixazomib Citrate | Overall Survival (OS) | NA months |
p-value: 0.8595% CI: [0.789, 1.332]Log Rank
Secondary
Percentage of Participants Who Develop a New Primary Malignancy
The decimal values of percentages were subjected to rounding off.
Time frame: Up to 107 months
Population: Safety Population was defined as participants who received at least 1 dose of ixzaomib citrate or placebo.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants Who Develop a New Primary Malignancy | 8 percentage of participants |
| Ixazomib Citrate | Percentage of Participants Who Develop a New Primary Malignancy | 7 percentage of participants |
Secondary
Percentage of Participants With Any Best Response Category Before PD or Subsequent Therapy
Response was assessed according to IMWG criteria. Best response includes partial response (PR), very good partial response (VGPR) and complete response (CR). PR as per IMWG criteria is 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to less than (\<)200 milligrams (mg) per 24 hours. VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours. CR is negative immunofixation of serum and urine and disappearance of soft tissue plasmacytomas and \<5% plasma cells in bone marrow. Stringent CR (sCR) is CR and normal FLC ratio and absence of clonal plasma cells (PCs) by immunohistochemistry or 2- to 4-color flow cytometry. The decimal values of percentages were subjected to rounding off.
Time frame: Randomization up to EOT (up to 24 months) and thereafter every 4 weeks until initiation of the next line of therapy (up to 107 months)
Population: ITT population was defined as all participants who were randomized and had post randomization data.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Percentage of Participants With Any Best Response Category Before PD or Subsequent Therapy | CR | 42 percentage of participants |
| Placebo | Percentage of Participants With Any Best Response Category Before PD or Subsequent Therapy | PR | 10 percentage of participants |
| Placebo | Percentage of Participants With Any Best Response Category Before PD or Subsequent Therapy | VGPR | 45 percentage of participants |
| Ixazomib Citrate | Percentage of Participants With Any Best Response Category Before PD or Subsequent Therapy | PR | 12 percentage of participants |
| Ixazomib Citrate | Percentage of Participants With Any Best Response Category Before PD or Subsequent Therapy | VGPR | 40 percentage of participants |
| Ixazomib Citrate | Percentage of Participants With Any Best Response Category Before PD or Subsequent Therapy | CR | 44 percentage of participants |
Comparison: CRp-value: 0.3795% CI: [0.365, 1.466]Cochran-Mantel-Haenszel
Secondary
PFS Benefits in a High-Risk Population
High-risk population included but not be limited to participants carrying deletion (del)17, t(4:14), t(14:16), amplification (ampl) 1q, del13, or del1p. PFS was defined as the time from the date of randomization to the date of first documentation of PD, as evaluated by an independent review committee according to IMWG criteria, or death due to any cause (whichever occurs first). PD is defined as ≥25% increase from lowest value in: serum/urine M-component; participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels must be \>10mg/dL; participants without measurable serum, urine M-protein levels and FLC levels, bone marrow plasma cell percent must be ≥10%;new bone lesions/soft tissue plasmacytomas development/existing bone lesions/soft tissue plasmacytomas size rise; hypercalcaemia development.
Time frame: Randomization up to 107 months
Population: ITT population was defined as all participants who were randomized and had post randomization data. Overall number of participants analyzed is the number of participants present in the high-risk group.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | PFS Benefits in a High-Risk Population | 16.8 months |
| Ixazomib Citrate | PFS Benefits in a High-Risk Population | 18.5 months |
Secondary
Plasma Concentration of Ixazomib
Plasma concentrations of the complete hydrolysis product of ixazomib citrate (ixazomib) were measured using a validated Liquid Chromatography-tandem Mass Spectrometry (LC/MS/MS) assay.
Time frame: Day 1 of Cycle 1: 1 hour and 4 hours post-dose; Predose on Days 8 and 15 of Cycle 1, Days 1 and 8 of Cycle 2, Day 1 of Cycles 3 through 10 (each cycle length= 28 days)
Population: The Pharmacokinetic (PK) Analysis Population was defined as participants with at least one PK sample that was collected and analyzed. Number analyzed is the number of participants with data available for analysis at the specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Plasma Concentration of Ixazomib | Cycle 1 Day 1: 1 Hour Post-dose | 27.919 nanograms per milliliter (ng/mL) | Standard Deviation 24.7787 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 1 Day 1: 4 Hours Post-dose | 10.352 nanograms per milliliter (ng/mL) | Standard Deviation 9.8078 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 1 Day 8 | 1.584 nanograms per milliliter (ng/mL) | Standard Deviation 1.6707 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 1 Day 15 | 2.611 nanograms per milliliter (ng/mL) | Standard Deviation 1.4305 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 2 Day 1 | 1.946 nanograms per milliliter (ng/mL) | Standard Deviation 1.0984 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 2 Day 8 | 3.232 nanograms per milliliter (ng/mL) | Standard Deviation 2.0069 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 3 Day 1 | 2.258 nanograms per milliliter (ng/mL) | Standard Deviation 1.1508 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 4 Day 1 | 2.396 nanograms per milliliter (ng/mL) | Standard Deviation 1.7822 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 5 Day 1 | 2.400 nanograms per milliliter (ng/mL) | Standard Deviation 1.4921 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 6 Day 1 | 2.623 nanograms per milliliter (ng/mL) | Standard Deviation 1.6994 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 7 Day 1 | 2.691 nanograms per milliliter (ng/mL) | Standard Deviation 1.9842 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 8 Day 1 | 2.637 nanograms per milliliter (ng/mL) | Standard Deviation 1.7074 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 9 Day 1 | 2.610 nanograms per milliliter (ng/mL) | Standard Deviation 1.938 |
| Placebo | Plasma Concentration of Ixazomib | Cycle 10 Day 1 | 2.594 nanograms per milliliter (ng/mL) | Standard Deviation 1.9509 |
Secondary
Second Progression Free Survival (PFS2)
PFS2 is defined as the time from the date of randomization to the date of objective disease progression on next line treatment or death from any cause (whichever occurs first). PD is defined as ≥25% increase from lowest value in: serum/urine M-component; participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels must be \>10 mg/dL; participants without measurable serum, urine M-protein levels and FLC levels, bone marrow plasma cell percent must be ≥10%; new bone lesions/soft tissue plasmacytomas development/existing bone lesions/soft tissue plasmacytomas size rise; hypercalcaemia development.
Time frame: Randomization up to EOT (24 months); thereafter followed up every 4 weeks until initiation of next-line therapy and then every 12 weeks until second progressive disease (PD2) or death (up to 107 months)
Population: ITT population was defined as all participants who were randomized and had post randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Second Progression Free Survival (PFS2) | 80.4 months |
| Ixazomib Citrate | Second Progression Free Survival (PFS2) | 84.0 months |
p-value: 0.90295% CI: [0.795, 1.298]Log Rank
Secondary
Time to End of the Next Line of Therapy
Time to end of the next line of therapy was defined as the time from the date of randomization to the date of last dose of the next line of antineoplastic therapy following study treatment or death due to any cause, whichever occurred first or date of last contact for participants who never took antineoplastic therapy.
Time frame: Randomization up to 107 months
Population: ITT Population was defined as all participants who were randomized and had post randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to End of the Next Line of Therapy | 50.4 months |
| Ixazomib Citrate | Time to End of the Next Line of Therapy | 55.9 months |
p-value: 0.43195% CI: [0.753, 1.129]Log Rank
Secondary
Time to Improvement of PN Events
PN is defined as the treatment-emergent adverse event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the Medical Dictionary for Regulatory Activities (MedDRA). A PN event is considered as resolved if its final outcome is resolved with no subsequent PN event of the same preferred term occurring on the resolution date or the day before and after. A PN event is considered as improved if the event improves from the maximum grade. That is, all the grades recorded after the maximum grade is less than the maximum grade. Time to improvement is defined as the time from the initial onset date (inclusive) of the maximum grade to the first onset date that the toxicity grade is below the maximum grade with no higher grade thereafter, or the resolution date, whichever occurs first.
Time frame: Up to 107 months
Population: Safety population was defined as participants who received at least 1 dose of ixazomib citrate or placebo. Overall number of participants analyzed indicates number of participants with peripheral neuropathy events.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Improvement of PN Events | 130.0 days |
| Ixazomib Citrate | Time to Improvement of PN Events | 134.0 days |
Secondary
Time to Progression (TTP)
TTP is defined as the time from the date of randomization to the date of first documentation of PD, using IMWG criteria. PD is defined as ≥25% increase from lowest value in: serum/urine M-component; participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels must be \>10mg/dL; participants without measurable serum, urine M-protein levels and FLC levels, bone marrow plasma cell percent must be ≥10%;new bone lesions/soft tissue plasmacytomas development/existing bone lesions/soft tissue plasmacytomas size rise; hypercalcaemia development. Participants without documentation of PD at the time of analysis were censored at the date of last response assessment that is stable disease or better.
Time frame: Randomization up to PD (up to 107 months)
Population: ITT Population was defined as all participants who were randomized and had post randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Progression (TTP) | 21.4 months |
| Ixazomib Citrate | Time to Progression (TTP) | 26.6 months |
p-value: 0.00295% CI: [0.579, 0.886]Log Rank
Secondary
Time to Resolution of Peripheral Neuropathy (PN) Events
Peripheral neuropathy is defined as the TEAE in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to Medical Dictionary for Regulatory Activities (MedDRA). A PN event is considered as improved if the event improves from the maximum grade. That is, all the grades recorded after the maximum grade is less than the maximum grade. Time to improvement is defined as the time from the initial onset date (inclusive) of the maximum grade to the first onset date that the toxicity grade is below the maximum grade with no higher grade thereafter, or the resolution date, whichever occurs first.
Time frame: Up to 107 months
Population: Safety population was defined as participants who received at least 1 dose of ixazomib citrate or placebo. Overall number of participants analyzed indicates the number of participants with peripheral neuropathy events.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Resolution of Peripheral Neuropathy (PN) Events | 159.0 days |
| Ixazomib Citrate | Time to Resolution of Peripheral Neuropathy (PN) Events | 225.0 days |
Secondary
Time to Start of the Next Line of Therapy
Time to start of the next line of therapy was defined as the time from the date of randomization to the date of initiation dose of the next line of antineoplastic therapy following study treatment or death due to any cause, whichever occurred first. Participants who never took antineoplastic therapy were censored at the date of last contact or death.
Time frame: Randomization up to 107 months
Population: ITT population was defined as all participants who were randomized and had post randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Start of the Next Line of Therapy | 27.6 months |
| Ixazomib Citrate | Time to Start of the Next Line of Therapy | 33.1 months |
p-value: 0.05695% CI: [0.69, 1.005]Log Rank